Filing Details

Accession Number:
0001209191-14-009941
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-12 19:55:07
Reporting Period:
2014-02-10
Filing Date:
2014-02-12
Accepted Time:
2014-02-12 19:55:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577014 P Jason Rhodes C/O Epizyme, Inc.
400 Technology Square
Cambridge MA 02139
President, Cfo And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2014-02-10 50,000 $3.54 54,000 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2014-02-10 20,000 $0.51 74,000 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2014-02-10 50,000 $29.25 24,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-02-10 50,000 $0.00 50,000 $3.54
Common Stock Stock Option (Right to Buy) Disposition 2014-02-10 20,000 $0.00 20,000 $0.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
260,833 2023-01-24 No 4 M Direct
292,459 2020-03-17 No 4 M Direct
Footnotes
  1. The sale transaction reported on this Form 4 was effected as a part of an underwritten public offering of common stock by Epizyme, Inc. with the Reporting Person as a selling stockholder in the offering.
  2. This option was granted on January 25, 2013 with respect to 310,833 shares of Common Stock, with 25% vesting on January 25, 2014 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
  3. This option was granted on March 18, 2010 with respect to 326,459 shares of Common Stock, with 25% vesting on March 12, 2011 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.